FLNA in HCC Patients

Hepatocellular Carcinoma Clinical Trial

Official title:

Filamin A Expression in HCC Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03081637
• Other study ID #: FLNA in HCC
• Status: Completed
• Phase: N/A
• First received: March 2, 2017
• Last updated: May 31, 2017
• Start date: January 1, 2004
• Est. completion date: March 2, 2017

Study information

• Verified date: May 2017
• Source: University of Milan
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The risk of recurrence after hepatectomy for hepatocellular carcinoma (HCC) is very high. Having a predictive marker of early recurrence (ER) would be desirable to personalize the follow-up and possibly develop new targeted therapy. The aim of this study was to test the expression of Filamin A (FLNA) in a cohort of patients operated for HCC.

Description:

A consecutive cohort of resected HCC patients will be analyzed. Several different prognostic factors, including FLNA expression, will be tested against the risk of ER. FLNA expression will be analyzed with immunohistochemistry in the intra-tumoral and extra-tumoral tissue compartments using a dedicated tissue microarray.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 115
• Est. completion date: March 2, 2017
• Est. primary completion date: December 31, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The inclusion criteria were represented by the histological positivity for HCC with complete clinical, surgical, pathological, and follow-up data.

Exclusion Criteria:

• Patients preoperatively treated with chemotherapy or trans-arterial therapy were excluded.

• Similarly, patients operated for recurrent HCC or with non-radical surgery or with missing data were excluded.

Related Conditions & MeSH terms

• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Milan

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of expression of Filamin A (FLNA) in HCC specimens from patients resected for HCC.	The rate of expression of FLNA in HCC specimens will be measured using standard immunohistochemistry methodology on surgical specimens. Such expression rate will be correlated to several different clinical and pathological parameters.	2 years after surgery as a minimum follow-up